JAK inhibitors may be used alternatively to treat ulcerative colitis
A new class of orally administered drugs has been included in the armamentarium of treatment for ulcerative colitis (UC), according to a recent study, which reports the effectiveness of Janus kinase (JAK) inhibitors, particularly tofacitinib.